Plain-English translation of NCT06355232 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new way to deliver COVID-19 and influenza vaccines by placing them under your tongue instead of injecting them into your arm. Researchers believe this approach may work better at stopping infection and transmission because it builds immunity at the surfaces where viruses first enter your body—your nose and throat. The study will compare three different dosing schedules to see which works best and is safest.
Current COVID-19 vaccines are good at preventing severe disease, but they don't stop infection or transmission very well because they work mainly in the bloodstream rather than where the virus first enters your body. This trial explores whether this medication, delivered to the mouth and throat surfaces, can create stronger protection against infection and spread.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to one of three groups. Depending on your group, you'll receive two doses of vaccine (or placebo) placed under your tongue, given two weeks apart. After three months, you'll receive two more doses of either a different vaccine or placebo, again two weeks apart. The entire study lasts about 6 months, and you'll need to avoid other COVID-19 and flu vaccines during this time.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
Australia
Sponsor
Vaxine Pty Ltd
Collaborators
Australian Respiratory and Sleep Medicine Institute
Enrollment target
~100 participants
Started
May 2024
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in September 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Sharen Pringle, GradCert
ARASMI
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.